Novo Nordisk Reports Strong Q1 Results Driven by Wegovy Weight-Loss Pill
Novo Nordisk reported first-quarter results that exceeded expectations, driven largely by strong demand for its new weight-loss pill, Wegovy. Despite a one-time gain inflating financial figures, the company raised full-year profit guidance and regained market share in the U.S., with prescriptions surging past two million.
Topics: market share Novo Nordisk pharmaceuticals Wegovy weight loss drugs